Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs.
about
Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancerChromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.Development of a qPCR Method to Measure Mitochondrial and Genomic DNA Damage with Application to Chemotherapy-Induced DNA Damage and Cryopreserved Cells.Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability.
P2860
Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Development and validation of ...... eatment with alkylating drugs.
@ast
Development and validation of ...... eatment with alkylating drugs.
@en
type
label
Development and validation of ...... eatment with alkylating drugs.
@ast
Development and validation of ...... eatment with alkylating drugs.
@en
prefLabel
Development and validation of ...... eatment with alkylating drugs.
@ast
Development and validation of ...... eatment with alkylating drugs.
@en
P2093
P2860
P1476
Development and validation of ...... reatment with alkylating drugs
@en
P2093
Aristotelis Bamias
Christina Bamia
Christina Liakou
Dimitra T Stefanou
Hara Episkopou
Margarita Bekyrou
Maria Gkotzamanidou
Petros P Sfikakis
Vassilis L Souliotis
P2860
P304
P356
10.1111/J.1365-2125.2012.04274.X
P407
P577
2012-11-01T00:00:00Z